The Global Drug sales of Xtandi stood at USD 5,885.52 Millions in 2022
The indicator recorded a historical growth (CAGR) of17% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti-neoplastic agent. It is formulated as soft gelatin capsules and tablets for oral route of administration.
Mechanism of Action
Enzalutamide is the first triple-acting, androgen receptor antagonist. It inhibits the activity of prostate cancer cell androgen receptors, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. Androgen receptor over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.
Xtandi Overview
Xtandi is marketed for the treatment of several indications in Infectious Disease, and Oncology therapy areas.
It is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel, indicated for the treatment of metastatic prostate cancer. It is also indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).
Xtandi was first approved in 2012 and is sold globally including the US, the UK, Australia, Germany, and Japan by Astellas Pharma Inc. Xtandi drug sales recorded a low-double digit Year on Year growth in 2022. Xtandi drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
2020: Does Immunotherapy Have a Future in Treating Prostate Cancer?
The treatment landscape for metastatic castrate-resistant prostate cancer (mCRPC) has shifted significantly in recent years. Chemotherapy, typically docetaxel or cabazitaxel, was the mainstay of mCRPC treatment until the development of drugs targeting the androgen receptor (AR). Johnson & Johnson’s Zytiga (abiraterone) and Astellas Pharma/Pfizer’s Xtandi (enzalutamide) are approved AR-antagonists that are now well-established as the standard of care for patients with mCRPC.
Immunotherapies have achieved significant milestones in a number of oncology indications—including melanoma, non-small cell lung cancer, and urothelial cancer. However, to date there has been little success within the mCRPC treatment landscape. The FDA approval of the personalized dendritic-cell-based vaccine, Dendreon’s Provenge (sipuleucel-T), for asymptomatic or minimally symptomatic mCRPC, is currently the only example of an immunotherapy approval for prostate cancer.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward